MUTATIONS IN THE LCAT GENE AND CLINICAL HETEROGENEITY: MAPPING GENOTYPE-PHENOTYPE CORRELATIONS
DOI:
https://doi.org/10.66104/9ty4ma64Keywords:
Genetic Heterogeneity, Lecithin Cholesterol Acyltransferase Deficiency, Plantar Plantar Disease, Lecithin Cholesterol Acyltransferase, Rare DiseasesAbstract
Lecithin-cholesterol acyltransferase (LCAT) deficiency is a rare autosomal recessive disorder characterized by significant genetic and phenotypic heterogeneity. More than 100 different mutations have been identified in the LCAT gene, resulting in two distinct clinical phenotypes: familial LCAT deficiency (FLD) and fisheye disease (FED). This study aimed to conduct an integrative literature review to identify and characterize mutations in the LCAT gene, emphasizing genotype-phenotype correlations and the mechanisms that determine clinical variability. An active search was conducted in electronic databases (PubMed, MedLine, SciELO, and LILACS) between January 2011 and December 2025, following PRISMA recommendations. Study selection was performed by two independent reviewers, analyzing titles, abstracts, and full texts, applying predefined inclusion and exclusion criteria. Nineteen studies describing specific mutations, clinical phenotypes, and biochemical data were included. The results demonstrate significant variation in the distribution of missense, nonsense, and frameshift mutations along the LCAT gene. Notable phenotypic heterogeneity was observed, with patients carrying identical genotypes presenting distinct clinical manifestations, including variations in renal involvement, ophthalmological manifestations, anemia, and lipid profile. A founder effect was identified in isolated populations, particularly in Brazilian families from Piauí. The genotype-phenotype correlation is not linear, suggesting an important role for genetic, environmental, and epigenetic modifying factors. These findings contribute to a better understanding of the molecular and clinical mechanisms of LCAT deficiency, fundamental for future diagnostic and therapeutic approaches in rare diseases.
Downloads
References
Akiko, T., Okura, T., Nagao, T., Kukida, M., Enomoto, D., Miyoshi, K. I., Higaki, J., Kuroda, M., & Bujo, H. (2016). A case of acquired lecithin:cholesterol acyltransferase deficiency with sarcoidosis that remitted spontaneously. CEN case reports, 5(2), 192–196. https://doi.org/10.1007/s13730-016-0223-4 DOI: https://doi.org/10.1007/s13730-016-0223-4
Ciro Acosta, S., Díaz-Ordóñez, L., Gutierrez-Medina, J. D., Silva-Cuero, Y. K., Arango-Vélez, L. G., García-Trujillo, A. O., & Pachajoa, H. (2024). Familial LCAT Deficiency and Low HDL-C Levels: In silico Characterization of Two Rare LCAT Missense Mutations. The application of clinical genetics, 17, 23–32. https://doi.org/10.2147/TACG.S438135 DOI: https://doi.org/10.2147/TACG.S438135
Calabresi, L., Simonelli, S., Gomaraschi, M., & Franceschini, G. (2012). Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis, 222(2), 299–306. https://doi.org/10.1016/j.atherosclerosis.2011.11.034 DOI: https://doi.org/10.1016/j.atherosclerosis.2011.11.034
Castro-Ferreira, I., Carmo, R., Silva, S. E., Corrêa, O., Fernandes, S., Sampaio, S., Pedro, R. P., Praça, A., & Oliveira, J. P. (2018). Novel Missense LCAT Gene Mutation Associated with an Atypical Phenotype of Familial LCAT Deficiency in Two Portuguese Brothers. JIMD reports, 40, 55–62. https://doi.org/10.1007/8904_2017_57 DOI: https://doi.org/10.1007/8904_2017_57
Coleman, B., Bedi, S., Hill, J. H., Morris, J., Manthei, K. A., Hart, R. C., He, Y., Shah, A. S., Jerome, W. G., Vaisar, T., Bornfeldt, K. E., Song, H., Segrest, J. P., Heinecke, J. W., Aller, S. G., Tesmer, J. J. G., & Davidson, W. S. (2025). Lecithin:cholesterol acyltransferase binds a discontinuous binding site on adjacent apolipoprotein A-I belts in HDL. Journal of lipid research, 66(5), 100786. https://doi.org/10.1016/j.jlr.2025.100786 DOI: https://doi.org/10.1016/j.jlr.2025.100786
Carty, J. R., & Anastasopoulou, C. (2024). Lecithin-Cholesterol Acyltransferase Deficiency. In StatPearls. StatPearls Publishing. Disponível em: https://pubmed.ncbi.nlm.nih.gov/38753926/. Acesso em: 8 dez. 2025.
de Serpa Brandão, R. M. S., Britto, F. B., do Monte Neto, J. T., Lima, M. C., do Monte, S. J. H., de Sousa Lima, A. V., Pereira, E. M., da Silva, H. J. N., Oliveira, D. M. T. E., Coelho, A. G. B., & da Silva, A. S. (2022). Familial lecithin-cholesterol acyltransferase deficiency: If so rare, why so frequent in the state of Piauí, northeastern Brazil?. Molecular genetics and metabolism reports, 30, 100840. https://doi.org/10.1016/j.ymgmr.2021.100840 DOI: https://doi.org/10.1016/j.ymgmr.2021.100840
Fotakis, P., Kuivenhoven, J. A., Dafnis, E., Kardassis, D., & Zannis, V. I. (2015). The Effect of Natural LCAT Mutations on the Biogenesis of HDL. Biochemistry, 54(21), 3348–3359. https://doi.org/10.1021/acs.biochem.5b00180 DOI: https://doi.org/10.1021/acs.biochem.5b00180
Fountoulakis, N., Lioudaki, E., Lygerou, D., Dermitzaki, E. K., Papakitsou, I., Kounali, V., Holleboom, A. G., Stratigis, S., Belogianni, C., Syngelaki, P., Stratakis, S., Evangeliou, A., Gakiopoulou, H., Kuivenhoven, J. A., Wevers, R., Dafnis, E., & Stylianou, K. (2019). The P274S Mutation of Lecithin-Cholesterol Acyltransferase (LCAT) and Its Clinical Manifestations in a Large Kindred. American journal of kidney diseases : the official journal of the National Kidney Foundation, 74(4), 510–522. https://doi.org/10.1053/j.ajkd.2019.03.422 DOI: https://doi.org/10.1053/j.ajkd.2019.03.422
Fistrek Prlic, M., Coric, M., Calabresi, L., Pavanello, C., Mosca, L., Cavallari, U., Vukovic Brinar, I., Karanovic, S., Laganovic, M., & Jelakovic, B. (2022). Two novel variants in the lecithin:cholesterol acyltransferase gene resulted in classic LCAT deficiency. Atherosclerosis plus, 49, 28–31. https://doi.org/10.1016/j.athplu.2022.05.005 DOI: https://doi.org/10.1016/j.athplu.2022.05.005
Gomaraschi, M., Ossoli, A., Castelnuovo, S., Simonelli, S., Pavanello, C., Balzarotti, G., Arca, M., Di Costanzo, A., Sampietro, T., Vaudo, G., Baldassarre, D., Veglia, F., Franceschini, G., & Calabresi, L. (2017). Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. Journal of lipid research, 58(5), 994–1001. https://doi.org/10.1194/jlr.P072371 DOI: https://doi.org/10.1194/jlr.P072371
Goñi Ros, N., González-Tarancón, R., Sienes Bailo, P., Salvador-Ruperez, E., Puzo Bayod, M., & Puzo Foncillas, J. (2022). A novel pathogenic variant in LCAT causing FLD. A case report. Acta clinica Belgica, 77(6), 970–975. https://doi.org/10.1080/17843286.2021.2007598 DOI: https://doi.org/10.1080/17843286.2021.2007598
Giorgi, L., Niemelä, A., Kumpula, E. P., Natri, O., Parkkila, P., Huiskonen, J. T., & Koivuniemi, A. (2022). Mechanistic Insights into the Activation of Lecithin-Cholesterol Acyltransferase in Therapeutic Nanodiscs Composed of Apolipoprotein A-I Mimetic Peptides and Phospholipids. Molecular pharmaceutics, 19(11), 4135–4148. https://doi.org/10.1021/acs.molpharmaceut.2c00540 DOI: https://doi.org/10.1021/acs.molpharmaceut.2c00540
Gao, H., Wu, J., Sun, Z., Zhang, F., Shi, T., Lu, K., Qian, D., Yin, Z., Zhao, Y., Qin, J., & Xue, B. (2022). Influence of lecithin cholesterol acyltransferase alteration during different pathophysiologic conditions: A 45 years bibliometrics analysis. Frontiers in pharmacology, 13, 1062249. https://doi.org/10.3389/fphar.2022.1062249 DOI: https://doi.org/10.3389/fphar.2022.1062249
Gomaraschi, M., Turri, M., Strazzella, A., Lhomme, M., Pavanello, C., Le Goff, W., Kontush, A., Calabresi, L., & Ossoli, A. (2023). Abnormal Lipoproteins Trigger Oxidative Stress-Mediated Apoptosis of Renal Cells in LCAT Deficiency. Antioxidants (Basel, Switzerland), 12(8), 1498. https://doi.org/10.3390/antiox12081498 DOI: https://doi.org/10.3390/antiox12081498
Holleboom, A. G., Kuivenhoven, J. A., Peelman, F., Schimmel, A. W., Peter, J., Defesche, J. C., Kastelein, J. J., Hovingh, G. K., Stroes, E. S., & Motazacker, M. M. (2011). High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in The Netherlands: identification and characterization of eight novel mutations. Human mutation, 32(11), 1290–1298. https://doi.org/10.1002/humu.21578 DOI: https://doi.org/10.1002/humu.21578
Hirashio, S., Ueno, T., Naito, T., & Masaki, T. (2014). Characteristic kidney pathology, gene abnormality and treatments in LCAT deficiency. Clinical and experimental nephrology, 18(2), 189–193. https://doi.org/10.1007/s10157-013-0895-4 DOI: https://doi.org/10.1007/s10157-013-0895-4
Human Genetics Mutation Database (HGMD®). (2025). Available at: http://www.hgmd.cf.ac.uk/ac/index.php
Lamiquiz-Moneo, I., Civeira, F., Gómez-Coronado, D., Blanco-Vaca, F., Villafuerte-Ledesma, H. M., Gil, M., Amigó, N., Mateo-Gallego, R., & Cenarro, A. (2019). Lipid Profile Rather Than the LCAT Mutation Explains Renal Disease in Familial LCAT Deficiency. Journal of clinical medicine, 8(11), 1860. https://doi.org/10.3390/jcm8111860 DOI: https://doi.org/10.3390/jcm8111860
Mahapatra, H. S., Ramanarayanan, S., Gupta, A., & Bhardwaj, M. (2015). Co-existence of classic familial lecithin-cholesterol acyl transferase deficiency and fish eye disease in the same family. Indian journal of nephrology, 25(6), 362–365. https://doi.org/10.4103/0971-4065.157802 DOI: https://doi.org/10.4103/0971-4065.157802
Miyata, M., Kuroda, M., Miyoshi, J., Kirinashizawa, M., Nagasawa, R., Yamamoto, M., Akasaki, Y., Utatsu, K., Maezawa, Y., Yokote, K., & Ohishi, M. (2025). Novel pathogenic variant in the LCAT gene in a compound heterozygous patient with fish-eye disease and a mild phenotype. Journal of clinical lipidology, 19(1), 125–133. https://doi.org/10.1016/j.jacl.2024.09.013 DOI: https://doi.org/10.1016/j.jacl.2024.09.013
Naito, S., Kamata, M., Furuya, M., Hayashi, M., Kuroda, M., Bujo, H., & Kamata, K. (2013). Amelioration of circulating lipoprotein profile and proteinuria in a patient with LCAT deficiency due to a novel mutation (Cys74Tyr) in the lid region of LCAT under a fat-restricted diet and ARB treatment. Atherosclerosis, 228(1), 193–197. https://doi.org/10.1016/j.atherosclerosis.2013.02.034 DOI: https://doi.org/10.1016/j.atherosclerosis.2013.02.034
Niemelä, A., & Koivuniemi, A. (2024). Systematic evaluation of lecithin:cholesterol acyltransferase binding sites in apolipoproteins via peptide based nanodiscs: regulatory role of charged residues at positions 4 and 7. PLoS computational biology, 20(5), e1012137. https://doi.org/10.1371/journal.pcbi.1012137 DOI: https://doi.org/10.1371/journal.pcbi.1012137
Ossoli, A., Neufeld, E. B., Thacker, S. G., Vaisman, B., Pryor, M., Freeman, L. A., Brantner, C. A., Baranova, I., Francone, N. O., Demosky, S. J., Jr, Vitali, C., Locatelli, M., Abbate, M., Zoja, C., Franceschini, G., Calabresi, L., & Remaley, A. T. (2016). Lipoprotein X Causes Renal Disease in LCAT Deficiency. PloS one, 11(2), e0150083. https://doi.org/10.1371/journal.pone.0150083 DOI: https://doi.org/10.1371/journal.pone.0150083
Oliaei, F., Batebi, B., Tabaripour, R., & Akhavan Niaki, H. (2019). Finding a very rare mutation in non-Caucasian LCAT patients from Southwest Asia for the first time. Journal of cellular biochemistry, 120(5), 7096–7100. https://doi.org/10.1002/jcb.27981 DOI: https://doi.org/10.1002/jcb.27981
Pavanello, C., Ossoli, A., Turri, M., Strazzella, A., Simonelli, S., Laurenzi, T., Kono, K., Yamada, K., Kiyosawa, N., Eberini, I., & Calabresi, L. (2020). Activation of Naturally Occurring Lecithin:Cholesterol Acyltransferase Mutants by a Novel Activator Compound. The Journal of pharmacology and experimental therapeutics, 375(3), 463–468. https://doi.org/10.1124/jpet.120.000159 DOI: https://doi.org/10.1124/jpet.120.000159
Roshan, B., Ganda, O. P., Desilva, R., Ganim, R. B., Ward, E., Haessler, S. D., Polisecki, E. Y., Asztalos, B. F., & Schaefer, E. J. (2011). Homozygous lecithin:cholesterol acyltransferase (LCAT) deficiency due to a new loss of function mutation and review of the literature. Journal of clinical lipidology, 5(6), 493–499. https://doi.org/10.1016/j.jacl.2011.07.002 DOI: https://doi.org/10.1016/j.jacl.2011.07.002
Reyes-Soffer, G., Matveyenko, A., Lignos, J., Matienzo, N., Santos Baez, L. S., Hernandez-Ono, A., Yung, L., Nandakumar, R., Singh, S. A., Aikawa, M., George, R., & Ginsberg, H. N. (2024). Effects of Recombinant Human Lecithin Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans. Arteriosclerosis, thrombosis, and vascular biology, 44(6), 1407–1418. https://doi.org/10.1161/ATVBAHA.123.320387 DOI: https://doi.org/10.1161/ATVBAHA.123.320387
Saeedi, R., Li, M., & Frohlich, J. (2015). A review on lecithin:cholesterol acyltransferase deficiency. Clinical biochemistry, 48(7-8), 472–475. https://doi.org/10.1016/j.clinbiochem.2014.08.014 DOI: https://doi.org/10.1016/j.clinbiochem.2014.08.014
Tietjen, I., Hovingh, G. K., Singaraja, R., Radomski, C., McEwen, J., Chan, E., Mattice, M., Legendre, A., Kastelein, J. J., & Hayden, M. R. (2012). Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT. Biochimica et biophysica acta, 1821(3), 416–424. https://doi.org/10.1016/j.bbalip.2011.08.006 DOI: https://doi.org/10.1016/j.bbalip.2011.08.006
Takahashi, S., Hiromura, K., Tsukida, M., Ohishi, Y., Hamatani, H., Sakurai, N., Sakairi, T., Ikeuchi, H., Kaneko, Y., Maeshima, A., Kuroiwa, T., Yokoo, H., Aoki, T., Nagata, M., & Nojima, Y. (2013). Nephrotic syndrome caused by immune-mediated acquired LCAT deficiency. Journal of the American Society of Nephrology : JASN, 24(8), 1305–1312. https://doi.org/10.1681/ASN.2012090913 DOI: https://doi.org/10.1681/ASN.2012090913
van den Bogaard, B., Holleboom, A. G., Duivenvoorden, R., Hutten, B. A., Kastelein, J. J., Hovingh, G. K., Kuivenhoven, J. A., Stroes, E. S., & van den Born, B. J. (2012). Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. Atherosclerosis, 225(2), 481–485. https://doi.org/10.1016/j.atherosclerosis.2012.09.022 DOI: https://doi.org/10.1016/j.atherosclerosis.2012.09.022
Vitali, C., Bajaj, A., Nguyen, C., Schnall, J., Chen, J., Stylianou, K., Rader, D. J., & Cuchel, M. (2022). A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency. Journal of lipid research, 63(3), 100169. https://doi.org/10.1016/j.jlr.2022.100169 DOI: https://doi.org/10.1016/j.jlr.2022.100169
Wang, X. L., Osuga, J., Tazoe, F., Okada, K., Nagashima, S., Takahashi, M., Ohshiro, T., Bayasgalan, T., Yagyu, H., Okada, K., & Ishibashi, S. (2011). Molecular analysis of a novel LCAT mutation (Gly179 → Arg) found in a patient with complete LCAT deficiency. Journal of atherosclerosis and thrombosis, 18(8), 713–719. https://doi.org/10.5551/jat.8003 DOI: https://doi.org/10.5551/jat.8003
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Higo José Neri da Silva , Ester Pereira Miranda, Deylane Menezes Teles e Oliveira , Keylla da Conceição Machado, Kátia da Conceição Machado, Pedro Agnel Dias Miranda Neto, Geyza Caroline Oliveira Pinto , Adalberto Socorro da Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;
Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;
Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);
Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.
PRIVACY POLICY
The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.
Note: All content of the work is the sole responsibility of the author and the advisor.
